Several pharmaceutical companies in Australia have indicated they will be looking for strategic alliances and joint ventures in the next two years, which could create opportunities for Australian biotechs, according to a 2015 PriceWaterhouseCoopers (PWC) survey of the Australian medicines industry.
Medicines Australia chief executive Tim James said: “The innovative, research-based medicines industry can play a key role in delivering a smarter, stronger, healthier Australia.”
The collaboration and investment could bring enormous benefits to the Australian economy, said Tim James. However, in order to achieve this, the policy-makers will need to help create the conditions that will attract investment, growth and job creation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze